Navigation Links
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Date:1/29/2009

eted an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine), and it has advanced AZ-104 (Staccato loxapine) into Phase 2b testing, both product candidates being developed for the acute treatment of migraine headache. AZ-002 (Staccato alprazolam) has completed Phase 1 testing and a Phase 2a proof-of-concept clinical trial. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at http://www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development, therapeutic potential, efficacy and safety of AZ-004. Any statement describing a product candidate or Alexza's goals, expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission including the risks under the heading: "We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations". Forward-looking statements
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
8. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
9. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
10. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
11. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Sigma-Aldrich Corporation (NASDAQ: ... under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) ... 22, 2014, thereby completing the U.S. HSR Act ... of the Company by Merck KGaA, Darmstadt, Germany.  ... condition to closing the transaction, which remains subject ...
(Date:12/22/2014)... Brussels (PRWEB) December 22, 2014 The ... the global leader of technical training across the life ... Clinical Data Management (SCDM) to provide the organization's ... certification programs —providing access to the more than 350 ... SCDM members with 10% off when registering for a ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy ... that it has signed a letter of intent ... has developed and patented a nanotechnology-based development platform ... products that enable rapid on-site collection and testing ... and health issues in an immediate, non-invasive and ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... 26, 2011 Mylan Inc. (Nasdaq: MYL ) today ... September 30, 2011. Financial Highlights ... 30 compared to $0.43 for the same prior year period; ... September 30 compared to $1.16 for the same prior year period; ...
... Calif., Oct. 25, 2011 Life Technologies Corporation ... Dx Genetic Analyzer has been approved by China,s State Food ... Dx is a capillary-based Sanger Sequencer intended for use in ... of genetic changes that may lead to disease presence or ...
... MENLO PARK, Calif. and IPSWICH, Mass., Oct. 25, 2011 ... of products and services for studying regulatory elements in ... New England Biolabs, Inc. (NEB) to create a new ... of SwitchGear,s LightSwitch™ Luciferase Assay System and NEB,s BioLux® ...
Cached Biology Technology:Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 2Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 3Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 4Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 5Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 6Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 7Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 8Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 9Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 10Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 11Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 12Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 13Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 14Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 15Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 16Life Technologies Launches 3500 Dx Series Genetic Analyzers for In Vitro Diagnostic Use in China 2Life Technologies Launches 3500 Dx Series Genetic Analyzers for In Vitro Diagnostic Use in China 3Life Technologies Launches 3500 Dx Series Genetic Analyzers for In Vitro Diagnostic Use in China 4SwitchGear Genomics and New England Biolabs Develop New Multiplex Reporter Assay System 2
(Date:12/5/2014)... Dec. 4, 2014  Tute Genomics, a leader in ... in Series A1 funding led by UK-based Eurovestech. Peak ... in the investment round. "We are at ... adopts next-generation sequencing and seeks new approaches for the ... Robison , MD MBA, and CEO of Tute Genomics. ...
(Date:11/21/2014)... 18, 2014 According to a ... Systems (Video, RFID, Access Control, Intrusion Detection, Parking Management, ... Government), Component Service Geography - Global Forecasts to 2020", ... projected to be around $25 Billion in 2014 and ... at a CAGR of 8.69%. Browse 116 ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... This news release is available in French . ... with today,s technology, it still takes both a male and a female ... raise that child? Many studies have outlined the value of a mother, ... New findings from the Research Institute of the McGill University Health Centre ...
... Dangerous Climate Change: Required Reductions of Carbon Emissions to ... Hansen and colleagues, and announces call for papers on ... assesses climate impacts of global warming using ongoing observations ... and simple representations of the global carbon cycle and ...
... Nov. 27, 2013 The mating roar of a male ... predator. Unfortunately for the seals, scientists have found evidence that ... present their work at the 166th Meeting of the Acoustical ... San Francisco, Calif. Previous research had shown mammal-eating killer ...
Cached Biology News:Dads: How important are they? 2Assessing dangerous climate change and call for climate change response papers 2Silent stalkers of dark ocean waters 2
A Highly Purified, Cost-Effective Taq DNA Polymerase...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
... SUPERaseIn RNase Inhibitor (patent pending) is a ... noncovalently binds and inhibits the most common ... C, 1 and T1. SUPERaseIn can be ... could be problematic. It is ideal for ...
... (Chemical Inkjet Printer) is a revolutionary ... and Protein Macroarray Analysis, developed in ... The strategy compliments established protocols in ... the proteins isoelectric point and apparent ...
Biology Products: